[go: up one dir, main page]

WO2011029954A3 - Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen - Google Patents

Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen Download PDF

Info

Publication number
WO2011029954A3
WO2011029954A3 PCT/EP2010/063475 EP2010063475W WO2011029954A3 WO 2011029954 A3 WO2011029954 A3 WO 2011029954A3 EP 2010063475 W EP2010063475 W EP 2010063475W WO 2011029954 A3 WO2011029954 A3 WO 2011029954A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosing
vascular diseases
polypeptide marker
assessing vascular
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/063475
Other languages
English (en)
French (fr)
Other versions
WO2011029954A2 (de
Inventor
Harald Mischak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mosaiques Diagnostics and Therapeutics AG
Original Assignee
Mosaiques Diagnostics and Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mosaiques Diagnostics and Therapeutics AG filed Critical Mosaiques Diagnostics and Therapeutics AG
Priority to US13/395,757 priority Critical patent/US20120241321A1/en
Priority to EP10775725A priority patent/EP2478377A2/de
Priority to JP2012528391A priority patent/JP2013504751A/ja
Publication of WO2011029954A2 publication Critical patent/WO2011029954A2/de
Publication of WO2011029954A3 publication Critical patent/WO2011029954A3/de
Anticipated expiration legal-status Critical
Priority to US14/497,613 priority patent/US20150018246A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Verfahren zur Diagnostik von vaskulären Erkrankungen umfassend den Schritt der Bestimmung einer An- oder Abwesenheit oder Amplitude von mindestens drei Polypeptidmarkern in einer Urinprobe, wobei die Polypeptidmarker ausgewählt sind aus den Markern, die in Tabelle 1 durch Werte für die Molekularmassen und die Migrationszeit charakterisiert sind.
PCT/EP2010/063475 2009-09-14 2010-09-14 Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen Ceased WO2011029954A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/395,757 US20120241321A1 (en) 2009-09-14 2010-09-14 Polypeptide marker for diagnosing and assessing vascular diseases
EP10775725A EP2478377A2 (de) 2009-09-14 2010-09-14 Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen
JP2012528391A JP2013504751A (ja) 2009-09-14 2010-09-14 血管疾患を診断および評価するためのポリペプチドマーカー
US14/497,613 US20150018246A1 (en) 2009-09-14 2014-09-26 Polypeptide marker for diagnosing and assessing vascular diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170190 2009-09-14
EP09170190.4 2009-09-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/395,757 A-371-Of-International US20120241321A1 (en) 2009-09-14 2010-09-14 Polypeptide marker for diagnosing and assessing vascular diseases
US14/497,613 Continuation US20150018246A1 (en) 2009-09-14 2014-09-26 Polypeptide marker for diagnosing and assessing vascular diseases

Publications (2)

Publication Number Publication Date
WO2011029954A2 WO2011029954A2 (de) 2011-03-17
WO2011029954A3 true WO2011029954A3 (de) 2011-06-16

Family

ID=43301867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/063475 Ceased WO2011029954A2 (de) 2009-09-14 2010-09-14 Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen

Country Status (4)

Country Link
US (2) US20120241321A1 (de)
EP (1) EP2478377A2 (de)
JP (1) JP2013504751A (de)
WO (1) WO2011029954A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008223791B2 (en) * 2007-03-07 2013-10-03 Mosaiques Diagnostics And Therapeutics Ag Method for the standardization of the concentration of analytes in a urine sample
EP1972940A1 (de) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Nierenerkrankungen
US9404932B2 (en) * 2007-11-05 2016-08-02 Nordic Bioscience A/S Pathology biomarker assay
EP2255203A2 (de) * 2008-03-19 2010-12-01 Mosaiques Diagnostics And Therapeutics AG Verfahren und marker zur diagnose von tubulären nierenschäden und -erkrankungen
US20110214990A1 (en) * 2008-09-17 2011-09-08 Mosaiques Diagnostics And Therapeutics Ag Kidney cell carcinoma
WO2013150132A2 (de) * 2012-04-05 2013-10-10 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung von schlaganfällen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063089A2 (de) * 2005-11-30 2007-06-07 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung vaskulären erkrankungen
WO2008008986A2 (en) * 2006-07-13 2008-01-17 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408372C (en) 2000-03-30 2010-10-19 Orde Levinson Urination apparatus
DE10021737C2 (de) 2000-05-04 2002-10-17 Hermann Haller Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063089A2 (de) * 2005-11-30 2007-06-07 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung vaskulären erkrankungen
WO2008008986A2 (en) * 2006-07-13 2008-01-17 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CARR STEVEN ET AL: "The need for guidelines in publication of peptide and protein identification data - Working group on publication guidelines for peptide and protein identification data", MOLECULAR & CELLULAR PROTEOMICS,, vol. 3, no. 6, 1 June 2004 (2004-06-01), pages 531 - 533, XP002616824 *
FLISER D ET AL: "Capillary electrophoresis coupled to mass spectrometry for clinical diagnostic purposes", ELECTROPHORESIS, WILEY INTERSCIENCE, DE, vol. 26, no. 14, 1 July 2005 (2005-07-01), pages 2708 - 2716, XP002381570, ISSN: 0173-0835, DOI: DOI:10.1002/ELPS.200500187 *
MOXON J V ET AL: "Challenges, Current Status and Future Perspectives of Proteomics in Improving Understanding, Diagnosis and Treatment of Vascular Disease", EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, SAUNDERS, LONDON, GB, vol. 38, no. 3, 1 September 2009 (2009-09-01), pages 346 - 355, XP026581442, ISSN: 1078-5884, [retrieved on 20090709], DOI: DOI:10.1016/J.EJVS.2009.05.008 *
THORSTEN KAISER: ""Proteomuntersuchung von Körperflüssigkeiten mittels online gekoppelter Kapillarelektrophorese-Massenspektrometrie als Routineverfahren der Diagnostik", Dissertation", INTERNET CITATION, 27 August 2004 (2004-08-27), pages 2PP, 1 - 173, XP002616825, Retrieved from the Internet <URL:http://deposit.d-nb.de/cgi-bin/dokserv?idn=985110600&dok_var=d1&dok_ext=pdf&filename=985110600.pdf> *
VON MUHLEN C Z ET AL: "Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients", JOURNAL OF PROTEOME RESEARCH, ACS, WASHINGTON, DC, US, vol. 8, no. 1, 2 January 2009 (2009-01-02), pages 335 - 345, XP002585193, ISSN: 1535-3893, [retrieved on 20081119], DOI: DOI:10.1021/PR800615T *
ZIMMERLI LUKAS U ET AL: "Urinary proteomic biomarkers on coronary artery disease", MOLECULAR & CELLULAR PROTEOMICS, vol. 7, no. 2, February 2008 (2008-02-01), pages 290 - 298, XP002619607, ISSN: 1535-9476 *

Also Published As

Publication number Publication date
JP2013504751A (ja) 2013-02-07
WO2011029954A2 (de) 2011-03-17
EP2478377A2 (de) 2012-07-25
US20150018246A1 (en) 2015-01-15
US20120241321A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
WO2008110593A3 (de) Verfahren und marker zur diagnose von nierenerkrankungen
WO2011029954A3 (de) Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen
WO2010041892A3 (ko) Aimp1 폴리펩티드의 신규한 용도
EP3413052A3 (de) Igfbp7 zur diagnose von diastolischer dysfunktion
WO2011027310A8 (en) Novel tumor markers
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2012024255A3 (en) Camkk-beta as a target for treating cancer
WO2011012268A8 (en) Use of mimecan in the assessment of heart failure
WO2009113814A3 (ko) 간암 진단용 단백질성 마커
WO2009115570A3 (de) Verfahren und marker zur diagnose von tubulären nierenschäden und -erkrankungen
EP3412779A3 (de) Verfahren zum nachweis von aviärer nekrotischer enteritis
WO2010041046A8 (en) Granin proteins as markers of heart disease
EP3173788A3 (de) Mittel und verfahren zur diagnose und therapie von erkrankungen
WO2011027308A8 (en) Novel tumor markers
WO2008155891A1 (ja) 新規な動脈硬化性疾患マーカー
WO2013113744A3 (de) Polypeptidmarker zur diagnostik und beurteilung der herzinsuffizienz
WO2009047280A3 (de) Polypeptidmarker zur diagnose von prostatakrebs
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
WO2009103061A3 (en) Methods and compositions for identifying, diagnosing, and treating neuroblastoma
WO2007140188A3 (en) Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
WO2009069132A3 (en) Novel reverse transcriptase inhibitors
WO2011027311A3 (en) Novel tumor markers
WO2013093356A3 (fr) Procede pour le diagnostic ou le pronostic, in vitro, du cancer du testicule
WO2011073901A8 (en) Novel tumor markers
WO2010121195A3 (en) Methods of inhibiting adverse cardiac events and treating atherosclerosis and coronary artery disease using galectin-3 binding protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10775725

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012528391

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010775725

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010775725

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13395757

Country of ref document: US